Polycystic Liver Disease

Gastroenterology
3
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
3
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
3100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Ipsen
IpsenChina - Tianjin
3 programs
2
Lanreotide Autogel 90 mg and 120 mgPhase 2/3Peptide1 trial
lanreotidePhase 2/3Peptide1 trial
LanreotideN/APeptide1 trial
Active Trials
NCT01354405Completed43Est. Jun 2014
NCT01315795Completed59Est. Jul 2014
NCT00771888Unknown54Est. Aug 2009
Camurus
CamurusSweden - Lund
1 program
1
CAM2029Phase 2/31 trial
Active Trials
NCT05281328Active Not RecruitingEst. Aug 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
CamurusCAM2029
IpsenLanreotide Autogel 90 mg and 120 mg
Ipsenlanreotide
IpsenLanreotide

Clinical Trials (4)

Total enrollment: 156 patients across 4 trials

NCT05281328CamurusCAM2029

A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD

Start: Jun 2022Est. completion: Aug 2027
Phase 2/3Active Not Recruiting
NCT01315795IpsenLanreotide Autogel 90 mg and 120 mg

Lanreotide Autogel in the Treatment of Symptomatic Polycystic Liver Disease

Start: Mar 2011Est. completion: Jul 201459 patients
Phase 2/3Completed
NCT00771888Ipsenlanreotide

Open-Label Extension of LOCKCYST Trial

Start: Apr 2008Est. completion: Aug 200954 patients
Phase 2/3Unknown
NCT01354405IpsenLanreotide

Somatostatin Analogues as a Volume Reducing Treatment of Polycystic Livers (RESOLVE)

Start: May 2011Est. completion: Jun 201443 patients
N/ACompleted

Related Jobs in Gastroenterology

Specialty Representative, Gastroenterology – Minneapolis, Minnesota

AbbVie
Remote
7h ago

Key Account Director, Diagnostics and Research

Tempus
Remote
20h ago
$150K - $200K/yr

Experienced Clin Programmer

Johnson & Johnson
High Wycombe, Buckinghamshire, United Kingdom
20h ago

[Innovative Medicine] Director, Government Affairs and Policy Dept., Integrated Market Access Div.

Johnson & Johnson
Chiyoda, Tokyo, Japan
20h ago

Analyst Accounting

Johnson & Johnson
Suzhou, Jiangsu, China
20h ago

Lead Product Security Engineer

Johnson & Johnson
Danvers, Massachusetts, United States of America
20h ago
$94K - $152K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

Peptide is the dominant modality (100% of programs)
2 companies competing in this space

Related Indications

Hepatic Impairment(79)Gastroesophageal Reflux Disease(37)Irritable Bowel Syndrome(29)Gastroesophageal Reflux(27)Liver Transplantation(24)Celiac Disease(23)Hepatic Insufficiency(22)Liver Cirrhosis(22)Gastroesophageal Reflux Disease (GERD)(14)Hepatic Encephalopathy(12)